Level of HER2/neu gene amplification as a predictive factor of response to trastuzumab-based therapy in patients with HER2-positive metastatic breast cancer

Overview of attention for article published in Investigational New Drugs, July 2008

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (72nd percentile)
Good Attention Score compared to outputs of the same age and source (70th percentile)

Mentioned by

patent: 2 patents

Citations

dimensions_citation: 21 Dimensions

Readers on

mendeley: 28 Mendeley

Summary Patents Dimensions citations

So far, Altmetric has seen 2 patents that reference this research output.

Genetic markers indicative of a cancer patient response to trastuzumab (herceptin)

Grant US-9677139-B2

United States of America

GENETIC MARKERS INDICATIVE OF A CANCER PATIENT RESPONSE TO TRASTUZUMAB (HERCEPTIN)

Application WO-2011072205-A2

World Intellectual Property Organisation (WIPO)

This page shows the most recent patents that mention this research output.

Click here to find out how to access more activity.